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Abstract
Background: One of the most commonly reported problems of randomised trials is that recruitment is usually
slower than expected. Trials will cost more and take longer, thus delaying the use of the results in clinical practice,
and incomplete samples imply decreased statistical power and usefulness of its results. We aim to identify barriers
and facilitators for successful patient recruitment at the level of the patient, the doctor and the hospital
organization as well as the organization and design of trials over a broad range of studies.
Methods/design: We will perform two cohort studies and a case-control study in the Netherlands. The first cohort
study will report on a series of multicenter trials performed in a nationwide network of clinical trials in obstetrics
and gynaecology. A questionnaire will be sent to all clinicians recruiting for these trials to identify determinants -
aggregated at centre level - for the recruitment rate. In a case control-study nested in this cohort we will interview
patients who refused or consented participation to identify factors associated with patients’ consent or refusal. In a
second cohort study, we will study trials that were prospectively registered in the Netherlands Trial Register. Using
a questionnaire survey we will assess whether issues on hospital organization, trial organization, planning and trial
design were associated with successful recruitment, i.e. 80% of the predefined number of patients recruited within
the planned time.
Discussion: This study will provide insight in barriers and facilitators for successful patient recruitment in trials. The
results will be used to provide recommendations and a checklist for individual trialists to identify potential pitfalls
for recruitment and judge the feasibility prior to the start of the study. Identified barriers and motivators coupled
to evidence-based interventions can improve recruitment of patients in clinical trials.
Background
Evaluation research is essential to inform evidence based
health care decisions. The randomized controlled trial
(RCT) is worldwide considered as the best instrument
to evaluate the effectiveness of medical interventions.
One of the most commonly reported problems with the
conduct of such RCTs, however, is that recruitment is
usually slower than expected. In the 1970’s an American
pharmacologist, Luis Lasagna, stated that once trial
recruitment starts, the supply of eligible patients
becomes a fraction of what was assumed before the
start of the trial. This phenomenon, currently known as
Lasagna’s Law, still holds today [1,2]. In the UK, in a
cohort of 114 multicenter trials funded by the UK Medi-
cal Research Councel and the UK Health Technology
Assessment Programme between 1994 and 2002, less
than one-third recruited their original target within the
time originally planned, and around one third had
extensions [1].
If in a clinical trial the targeted sample size is not
achieved, it will have less statistical power to convin-
cingly demonstrate potentially important differences
between the groups, which might make the results less
useful or not at all applicable in clinical practice - it will
not improve practice and wastes the contribution of par-
ticipants who already participated. In addition, if recruit-
ment has to be extended to reach the required sample
size, the trial will cost more and take longer, thus
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delaying the use of its results in clinical practice. As the
total amount of funding is limited, fewer trials can be
conducted and hence less clinical dilemmas can be
solved.
Reasons for lack of recruitment can be found at differ-
ent levels: the patient, the doctor, the participating cen-
tre or department, the study organisation and the study
design (see figure 1) [1,3-7].
Rendell et al. reviewed incentives and disincentives to
participation, focussing on participation of clinicians [6].
Lovato et al. and Ross et al. reviewed barriers to both
patient and clinician participation [4,8]. Other reviews
were dedicated to a specific disease or group of diseases
[3,9-13]. Frequently mentioned barriers for patients are
preference for one form of treatment, concerns with the
trial setting, dislike of randomisation, general discomfort
with the research process, distrust in researchers, com-
plexity and stringency of the protocol, presence of a pla-
cebo or no-treatment group, potential side effect, fear
that trial involvement would have a negative effect on the
relationship with their physician and their physicians atti-
tudes towards the trial, the potential for increased
demands and the mere inability to make a decision
[13,14]. Frequently mentioned barriers to clinician parti-
cipation are time constraints, lack of staff and training,
worry about the impact on doctor-patient relationship,
concern for patients, loss of professional autonomy, diffi-
culty with the consent procedure, lack of rewards and
recognition, and an insufficiently interesting question [4].
These reasons might be different across specialties,
countries or due to the nature of the disease or disease
population, but will probably also have common
denominators [10]. In many of the included papers in
the reviews it is uncertain if and how these results can
be generalized to other trials and populations. In the
reviews there might also be an over representation of
very successful or very unsuccessful recruiting trials, as
especially these trials might invoke a study of determi-
nants of recruitment by the trial coordinator. Recently,
the STEPS study focused on recruitment from different
perspectives, and although they identified determinants,
they did not have sufficiently definitive results to make
strong recommendations [1].
In conclusion, although several potential barriers have
been identified, it remains unclear whether they are
applicable for any next trial. At present, neither a rule
which can predict successful recruitment, nor a checklist
to assess the feasibility of recruitment prior to the start
of a trial, or even prior to a funding decision, is avail-
able. We therefore aim to study methods for IMproving
PArticipation in Clinical Trials (IMPACT). We aim to
identify predictors for (un)successful patient recruitment
at the level of the patient, the doctor and the study and
organizational level in order to provide a rule or check-
list for successful patient recruitment in clinical trials.
Methods/design
To address this topic at different relevant levels, we plan
two cohort studies and a nested case control study in
The Netherlands. In the first cohort study we will focus
on successful recruitment at the level of participating
centres, where characteristics of the clinician will be
aggregated at the level of the centre. In a case control
study embedded in this cohort study we will focus on
the patient level. In the second cohort study we will
identify determinants for success of recruitment in a
cohort of trials registered in the national Netherlands
Trial Register.
This study did not require formal approval of an
ethics committee or internal review board, as was con-
firmed by the ethics committee of the Academic Medi-
cal Center. We interpreted completion and return of a
questionnaire as the respondent’s consent for participa-
tion. Methodological details of these studies are
described below.
Cohort study 1: predicting recruitment at centre level
The first cohort aims to determine which factors on
centre level will influence recruitment of patients. The
cohort will consist of a series of multicenter trials per-
formed in a nationwide Consortium on studies in
Obstetrics and Gynaecology, in which currently over 70
medical centres participate (table 1) [15]. At the centre
level, we will study aspects of the doctor as well as
aspects of the organisation. A questionnaire will be sent
to gynaecologists, residents, research nurses, and mid-
wives in the Netherlands who work in centres recruiting
for these trials. We will also collect data on characteris-
tics of clinicians and study organization.
Based on these data, we will construct a prediction
model. The primary outcome will be the percentage of
eligible patients recruited, defined as the number of ran-
domized patients per centre divided by the number of
eligible patients. Secondary outcomes will be the num-
ber of randomized patients divided by the number of
Figure 1 Factors for lack of recruitment can be found on
different levels: with interactions between levels.
Oude Rengerink et al. BMC Medical Research Methodology 2010, 10:85
http://www.biomedcentral.com/1471-2288/10/85
Page 2 of 6
available patients per centre stratified per study. The
number of eligible patients is registered for a part of the
studies and will be estimated based on the LVR, the
Dutch national perinatal registry.
As potential predictors we will take into account char-
acteristics of the clinicians, e.g. the proportion of doctors
with a PhD, as well as clinicians’ views on the trial, e.g.
prior belief in the relevance and quality of the study
design. We will also collect characteristics of the study
organisation: e.g. status of the hospital (academic, teach-
ing or general), availability of research nurses or employ-
ees for counselling of the studies, clarity of research
protocol and logistics, responsibilities for recruitment.
These potential predictors reflect clinicians’ views on
these topics, aggregated at the level of department.
For reliable modelling on prediction experts recom-
mend that there should be at least about 10 events in
the data set for each potential predictor to be included
in the model [16]. As we expect a response in about 65
of 70 centres, prediction models can include about 6-7
predictors at centre level.
Missing values will be imputed. The predictive accu-
racy of the model will be assessed using calibration,
which evaluates the correspondence between the mod-
el’s predicted percentage of randomized patients and the
observed percentage of randomized patients. The discri-
minative ability of the prognostic model will be assessed
by using receiver operating characteristics (ROC) analy-
sis. We will then perform internal validation using boot-
strapping and apply shrinkage to correct for over fit.
A simplified prediction rule will be derived from the
regression coefficients of the independent predictors in
the multivariable model. If a valid prediction rule cannot
be constructed, we will use the multivariable model to
identify risk factors for a low recruitment percentage.
Case-control study: predicting recruitment at patient level
In a case control-study nested in this cohort we will
interview patients who refused or consented participa-
tion in a set of clinical trials, to identify factors which
influenced the decision to participate.
We will perform qualitative semi-structured inter-
views. The interviews will start with open questions on
the motivation of a patient to consent or refuse partici-
pation. Subsequently, the interview will be guided by a
topic list that is based on the literature and on input
Table 1 A cohort of studies performed in a nationwide Consortium on studies in obstetrics and gynaecology in the
Netherlands
Nr Trial Population Sample size
1 Amphia Women with a multiple pregnancy before 20 weeks pregnancy 720
2 Hypitat II Women with pregnancy induced hypertension or mild pre-eclampia at 34-37 weeks gestation 400
3 Digitat Women with a singleton pregnancy at 36 completed weeks of gestation or more 626
4 Ppromexil Women with preterm prelabour rupture of membranes between 34 and 37 weeks gestation 520
5 Stan Women in labour over 36 weeks of gestation with an indication for CTG monitoring 2400
6 Apostel 1 Women with threatened preterm labour at 24-34 weeks gestation. 220
7 Apostel 2 Women with threatened preterm labour at 26-32+2 weeks gestation. 400
8 TRIPLE P Women with a singleton pregnancy 1920
9 Probaat Women ≥ 37 weeks of gestation and Bishop score < 6 812
10 PreCare Women with preeclampia or HELLP in previous pregnancy 250
11 WOMB Women with >1000 mL postpartum fluxus 400
12 Truffle Women at 26-32 weeks gestation with a fetus with intrauterine growth retardation. 500
13 Allo Women with suspected fetal asphyxia during labour 220
14 ProTWIN Women with a multiple pregnancy between 12 and 20 weeks gestation 660
15 Metex Women with an extra uterine gravidity 72
16 ESEP Women with an extra uterine gravidity in one of the tubae and a normal contralateral tuba 450
17 INeS Couples with unexplained subfertility or a mild male factor 600
19 MOVIN’ Women with anovulation not pregnant after 6 ovulatory cycles of clomid 200
20 Bedrest Women who undergo intra-uterin insemination 250
21 VUSIS 1 Women with stress-incontinence 100
22 PORTRET Women with stress incontinence aged 35-80 years 400
23 CUPIDO Women with vaginal prolaps 114
24 Pompoen Women with postmenopausal bleeding 200
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from experienced trialists. Topics will include counsel-
ling, clarity and understanding of patient information,
knowledge of and attitude towards scientific research
[9,17], attitude towards the doctor or health care organi-
sation, type of intervention, practical considerations and
organisational issues, (perceived) personal benefit, (dis)
trust and their social demographic characteristics. This
topic list will be tailored during the study.
We will interview patients who were recently coun-
selled for participation in a RCT in a broad range of
trials in the field of obstetrics, subfertility, gynaecology,
internal medicine, neurology and surgery. Patients will
be selected using purposive sampling. We will interview
patients from different doctors, different natures of dis-
ease, different levels of education, and different regions
in the Netherlands. The number of patients to be inter-
viewed will be dependent on the variety of responses
until saturation of the data is reached. We expect this to
be about 10 patients who participated and 10 patients
who refused for the first subspecialty obstetrics. As we
assume that reasons for the decision about participation
share common components across specialties, we can
complete the reasons with a smaller sample of patients
from other clinical specialties. This will provide us infor-
mation about the full spectrum of barriers and facilita-
tors for participation.
Based on these barriers and motivators observed in
the interviews we will construct a questionnaire to
quantify these findings in a representative sample of
patients in the fields of obstetrics and gynaecology, neu-
rology, surgery and internal medicine.
Cohort study 2: Predicting recruitment success of trials
registered in the Netherlands Trial Register
In a second cohort study, we will include study trials
that have been registered prospectively in the Nether-
lands Trial Register. The cohort of studies will consist
of all studies that registered their stop date between Jan-
uary 1st 2005 and January 1st, 2010 (expected number of
available trials N≈1000). Using a questionnaire survey,
we will investigate whether issues on hospital organiza-
tion, trial organization, planning and trial design are
predictive for successful recruitment, defined as ≥80% of
the patients recruited within the time frame defined in
the grant application.
As potential predictors we will take into account
trial characteristics, i.e. placebo arm, blinding, experi-
mental status of the intervention to be evaluated;
characteristics of the trial organisation, i.e. research
staff available to counsel patients and acquire follow
up data, who is responsible for recruitment; and char-
acteristics of the principal investigator and the
research group, i.e. composition of different expertise,
experience and training in trial research. For reliable
prediction modelling experts recommend that there
should be at least about 10 events in the data set for
each potential predictor to be included in the model
[16]. In a sample of 1000 studies, with a (low) recruit-
ment rate of 30% about 30 potential predictors can be
tested reliably.
Missing values will be imputed. Like in the cohort
study I, the predictive accuracy of the model will be
assessed using calibration, which evaluates the corre-
spondence between the model’s predicted probabilities
of recruitment success and the observed recruitment
success over groups. The discriminative ability of the
prognostic model will be assessed by using receiver
operating characteristics (ROC) analysis.
We will perform internal validation using bootstrap-
ping and apply shrinkage to correct for over fit.
A prediction rule will be derived from the regression
coefficients of the independent predictors in the multi-
variable prognostic model. If a valid prediction rule can-
not be constructed, we will use the model to identify
risk factors for a low recruitment percentage.
Discussion
At the end of the study, we will have an inventory of
predictors, barriers and facilitators for successful patient
recruitment in trials. The first cohort study will provide
information on prediction of recruitment in different
centres participating in obstetrical, subfertility and
gynaecological trials. From the nested case-control study
we will obtain qualitative and quantitative information
about factors which influence patient participation. The
second cohort study will provide insight in factors
related to successful recruitment at study level. Based
on the prediction models or risk factors for unsuccessful
recruitment, we will develop a set of recommendations
and a checklist that can be used by individual trialists
before the start of the study to assess if recruitment of
the proposed sample size with their strategy will be
feasible.
A strong point of the design is that we will address
recruitment factors at different levels and from different
perspectives, throughout a variety of trials in various
fields of medicine. This will provide us with a broad
overall picture of reasons why patients participate or
refuse participation, and will provide insight in a com-
mon denominator between trials, or clarify differences.
At the same time this is a potential pitfall: the reasons
for participation or non-participation in a clinical trial
might predominantly depend on exclusive characteristics
of a trial and its targeted population, so that general
predictors may not be identified. If so, the results are
still valuable, but we should focus on the development
of a general applicable recruitment tool. Such a tool
might consist of a strategy based on interviewing a
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number of eligible participants as well as a number of
recruiters and/or clinicians prior to start or during the
piloting of the trial.
Another strong point is that the first cohort is based on
clinicians recruiting for a set of trials from the nationwide
consortium in Obstetrics and Gynaecology. All academic
medical centres and the majority of the Dutch hospitals
recruit for trials running in this consortium, which
enables us to cover a large part of the Netherlands with-
out selection of the explicitly research minded hospitals.
Moreover, the second cohort of studies from the Dutch
Trial Register will be a representative sample of all trials
performed in the Netherlands, since from July 2005 regis-
tration is required for publication in important journals.
It will be a challenge to deliberately handle the heteroge-
neity of the trials included.
There are also some limitations in this study which
require a remark. First, although we focus on different
levels (level of the patient, centre and study) it is not
possible to directly link the data from these levels. We
therefore cannot disentangle the relative impact of each
level to the recruitment problems. However, we will be
able to provide a satisfactory estimation, given the varia-
bility between different specialties and trials.
Second, as we focus on trials in obstetrics and gynae-
cology in the first cohort study, generalisability of these
results to other clinical specialties should be evaluated.
As in this study it is not feasible to survey all specialties
in depth, we think it is more informative to have a com-
plete picture of one specialty over a limited amount of
information from many specialties.
Furthermore, in the second cohort on predicting
successful recruitment on study level, the predefined
recruitment target will probably - as most power cal-
culations - be based on limited information. When
information emerges from external sources or interim
analyses, the sample size might be adapted, which can
make the trial more successful or efficient without
reaching the originally planned sample size. However,
sample size targets are taken into account when fund-
ing decisions are made. The extent to which a trial
meets initial expectations can be viewed as a legiti-
mate marker of trial success. Moreover, recruitment
can be viewed of as a surrogate marker of more sig-
nificant markers of success, such as the extent to
which the trial question has been successfully
addressed [1].
Interviewing patients from different specialties and
trials will provide a broad spectrum of why patients par-
ticipate or refuse. This will limit the number of patients
interviewed from one trial, but the quantification of
these reasons in a representative group of patients will
allow us to examine differences between these special-
ties and trials.
Finally, as this study will be performed in the Nether-
lands, the Dutch health care system as well as the posi-
tion of medical research in the Netherlands might
influence its results. Existing literature can be used to
compare our results with those from other countries.
We realize that especially to make this study a success
we need a high response rate to avoid selection of highly
motivated researchers, patients and clinicians.
In conclusion, this design allows us to identify deter-
minants for unsuccessful recruitment. Identified predic-
tors for unsuccessful recruitment can be coupled to
evidence-based strategies to improve recruitment in
trials [7].
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